|Videos|September 21, 2017

What Are the Next Steps for Iclaprim?

David Huang, PhD, MD, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections.

David Huang, PhD, MD, chief medical officer at Motif Bio, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections. Dr. Huang shares that if the results of REVIVE 2 are favorable, then he and his team will submit a new drug application to the US Food and Drug Administration in the first half of next year.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.